What is Mercy Bioanalytics?
Mercy Bioanalytics, Inc. is a pioneering biotechnology enterprise dedicated to reducing mortality rates through the early identification of cancer. The company utilizes a sophisticated platform that isolates extracellular vesicles—nanoparticles abundant in the bloodstream that carry critical biological information from parent cells. By decoding these signals, Mercy Bioanalytics offers a non-invasive diagnostic solution that addresses the urgent clinical need for earlier detection in high-risk patient populations. Positioned at the intersection of liquid biopsy innovation and precision medicine, the company is currently scaling its operations to address significant gaps in current screening protocols for aggressive cancer types.
How much funding has Mercy Bioanalytics raised?
Mercy Bioanalytics has raised a total of $100M across 2 funding rounds:
Series A
$41M
Series B
$59M
Series A (2023): $41M with participation from iSelect Fund Management, Novalis LifeSciences, Sozo Ventures, and Hatteras Venture Partners
Series B (2025): $59M led by Portfolia, Sozo Ventures, Avestria Ventures Management, BrightEdge - American Cancer Society, Hologic, Novalis Trust, Xontogeny, iSelect Fund Management, Labcorp, and Bruker Scientific
Key Investors in Mercy Bioanalytics
Sozo Ventures
Sozo Ventures is an expansion-stage VC firm focused on connecting the most ambitious entrepreneurial teams with the world's most advanced and respected customers across the globe.
BrightEdge - American Cancer Society
BrightEdge operates at the intersection of investment and innovation to drive scientific, social, and sustainable impact across the continuum of cancer care as the innovation and impact investment arm of the American Cancer Society.
Labcorp
Labcorp Holdings Inc. operates as a laboratory services company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions.
What's next for Mercy Bioanalytics?
With the successful closure of this latest funding round, Mercy Bioanalytics is well-positioned to scale its clinical proof-of-concept studies and expand its diagnostic pipeline. The strategic focus will likely shift toward navigating complex regulatory pathways and establishing commercial partnerships with major healthcare providers to integrate their technology into standard clinical workflows. By maintaining a rigorous focus on evidence-based outcomes, the company aims to solidify its market position as a leader in the next generation of cancer diagnostics, ultimately improving patient survival rates through earlier, more accurate intervention.
See full Mercy Bioanalytics company page
